Subcutaneous · GLP-1 agonist
AC2592
1 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
1
Sites
29
Countries
1
Endpoints
3
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 2
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Heart failure
3
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00099580PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure | AC2592 Heart failure | HbA1c ≤11% | Ph 2 | Completed | 29 | Sep 2006 | - |
Showing 1-1 of 1 trials